We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $111.08 · 12 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Stored first · Google News · Yahoo Finance (English)
GMED's Robotics Leasing Shift Could Build Recurring Revenue - Yahoo Finance
GMED's Robotics Leasing Shift Could Build Recurring Revenue Yahoo Finance
Globus Medical Inc - A (NYSE:GMED) Shines in Decent Value Screen with Strong Fundamentals - ChartMill
Globus Medical Inc - A (NYSE:GMED) Shines in Decent Value Screen with Strong Fundamentals ChartMill
GMED Growth Drivers After NuVasive and What Q1 Signals - Zacks Investment Research
GMED Growth Drivers After NuVasive and What Q1 Signals Zacks Investment Research
Globus Medical Inc (GMED) Shares Fall 3.0% -- What GF Score of 9 - GuruFocus
Globus Medical Inc (GMED) Shares Fall 3.0% -- What GF Score of 9 GuruFocus
Looking for a growth stock? 3 reasons why Globus Medical (GMED) is a solid choice - MSN
Looking for a growth stock? 3 reasons why Globus Medical (GMED) is a solid choice MSN
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 06. | After market close (AMC) | $1.1 | — | — | $783.82M | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $0.54 | — | — | $598.12M | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $0.56 | — | — | $1.86B | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $0.18 | — | — | $1.24B | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 09. | RBC Capital | — | Maintain | Outperform → Outperform | — | RBC Capital: Outperform |
| 2026. 05. 08. | Wells Fargo | — | Maintain | Overweight → Overweight | — | Wells Fargo: Overweight |
| 2026. 05. 08. | Needham | — | Maintain | Buy → Buy | — | Needham: Buy |
| 2026. 02. 27. | Wells Fargo | — | Maintain | Overweight → Overweight | — | Wells Fargo: Overweight |
| 2026. 02. 26. | Barclays | — | Maintain | Overweight → Overweight | — | Barclays: Overweight |
| 2026. 02. 25. | Needham | — | Maintain | Buy → Buy | — | Needham: Buy |
As of FY2026Q1 · Source: SEC/DART + price data
No holdings data to show.